Prime Capital Investment Advisors’s United Therapeutics UTHR Stock Holding History

Prime Capital Investment Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$567K	Sell	1,046 -48	-4%	-$27K	0.01%	662
2026 Q1	$649K	Sell	1,094 -25	-2%	-$12.4K	0.01%	609
2025 Q4	$545K	Sell	1,119 -103	-8%	-$48K	0.01%	625
2025 Q3	$512K	Buy	1,222 +19	+2%	+$6.39K	0.01%	629
2025 Q2	$346K	Sell	1,203 -704	-37%	-$210K	﹤0.01%	719
2025 Q1	$588K	Buy	1,907 +477	+33%	+$163K	0.01%	628
2024 Q4	$505K	Buy	1,430 +54	+4%	+$19.8K	0.01%	567
2024 Q3	$493K	Sell	1,376 -20	-1%	-$6.76K	0.01%	591
2024 Q2	$445K	Buy	1,396 +384	+38%	+$102K	0.01%	606
2024 Q1	$232K	Buy	1,012 +6	+0.6%	+$1.35K	﹤0.01%	872
2023 Q4	$221K	Buy	1,006 +44	+5%	+$10.1K	﹤0.01%	848
2023 Q3	$217K	Sell	962 -9	-0.9%	-$2.07K	﹤0.01%	666
2023 Q2	$214K	Buy	+971	New	+$215K	﹤0.01%	690

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Prime Capital Investment Advisors's UTHR Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its United Therapeutics (UTHR) stake by 4.4% in Q2 2026, selling an estimated $27K and leaving 1,046 shares worth $567K. The position accounts for 0.01% of the portfolio, ranked #662.

Prime Capital Investment Advisors first reported a position in UTHR in Q2 2023 and has held it in 13 quarters since. The position peaked at $649K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Prime Capital Investment Advisors held 1,046 shares of United Therapeutics worth $567K as of Q2 2026.
Prime Capital Investment Advisors sold 48 United Therapeutics shares in Q2 2026, an estimated $27K.
United Therapeutics made up 0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #662 holding.
Prime Capital Investment Advisors first reported a position in United Therapeutics in Q2 2023 and has held it in 13 quarters since.
Prime Capital Investment Advisors's United Therapeutics position peaked at $649K in Q1 2026.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.